New UK research reveals that combining weight loss injections with coaching and regular weight tracking can boost effectiveness by 53%, highlighting the importance of behavioural support in obesity treatment.
The study, led by Voy and Imperial College London, analysed data from nearly 60,000 patients using weight loss medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro). It found that those who incorporated digital tools like coaching and weight monitoring into their treatment saw significantly greater results compared to those using medication alone.
The findings emphasise that injectable weight loss treatments are most effective when paired with long-term lifestyle changes. Patients who weighed themselves at least once per week or participated in even one coaching session lost 53% more weight than those who relied solely on medication. The combination of coaching and regular tracking delivered the most noticeable progress within just four months.
The research also revealed that higher engagement led to better outcomes. Users who consistently interacted with Voy’s behaviour change tools lost more weight and built more sustainable habits.
There were also notable differences between age and gender groups. Women aged 55 and over were the most engaged, tracking their weight six times per month on average and attending five coaching sessions per programme. Men aged 18 to 24 were the least engaged, averaging just three monthly weight logs and fewer than one coaching session.
The study highlighted regional variations in weight loss results. The greatest success rates were recorded in Scotland, Wales, Northern Ireland, the West Midlands and the South East, suggesting the potential benefit of more tailored, localised support strategies.
Even small changes made a measurable difference. Patients who joined two coaching sessions per month lost 6% more weight, while those tracking their weight nine to twelve times per month saw a 3% improvement. With a 10% reduction in body weight linked to significantly lower risks of diabetes and heart disease, these improvements are clinically important.
The results support a growing consensus that GLP-1 weight loss injections are not a standalone solution. Instead, they are most effective when combined with behaviour change support, including coaching, tracking, and digital engagement.
Voy’s programme integrates prescription medication with personalised coaching and a user-friendly app, helping patients adopt healthier habits and monitor their progress over time.
Those considering weight loss injections should seek professional medical advice, as eligibility varies and not all individuals are suitable candidates for these treatments.
